DaVita (NYSE:DVA) Hits New 1-Year High – Time to Buy?

Shares of DaVita Inc. (NYSE:DVA) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $172.17 and last traded at $172.71, with a volume of 12210 shares. The stock had previously closed at $170.28.

Analysts Set New Price Targets

DVA has been the topic of several research analyst reports. Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, DaVita has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Stock Up 2.1 %

The company has a fifty day moving average price of $158.32 and a 200-day moving average price of $154.01. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The firm has a market capitalization of $14.26 billion, a PE ratio of 18.74, a PEG ratio of 0.82 and a beta of 0.92.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.85 EPS. As a group, analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

Hedge Funds Weigh In On DaVita

Large investors have recently modified their holdings of the stock. Transcendent Capital Group LLC purchased a new position in DaVita during the third quarter worth $25,000. Blue Trust Inc. raised its position in DaVita by 56.4% in the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after purchasing an additional 119 shares during the period. Quarry LP bought a new stake in DaVita in the third quarter worth about $60,000. Versant Capital Management Inc boosted its position in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares during the period. Finally, ORG Wealth Partners LLC purchased a new stake in shares of DaVita in the third quarter worth approximately $97,000. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.